Drug intelligence / Profile preview

paeoniflorin + cervus and cucumis polypeptide

Development stage: Unknown
Modality: Peptides, Small Molecules
Administration: Intramuscular, Oral

Overview

A traditional Chinese medicine combination used primarily for treating rheumatoid arthritis. The formulation consists of paeoniflorin (PAE), which has anti-inflammatory properties, and cervus and cucumis polypeptide injection (CCPI), which has bone healing, pain relieving, and anti-inflammatory properties. Clinical studies indicate that while this combination may not be as effective as conventional disease-modifying antirheumatic drugs (DMARDs) for long-term treatment of rheumatoid arthritis, it appears to have a faster onset of action and fewer adverse effects.

Brand names: Pafulin + Songmeile
Other names: PAE + CCPI

Targets

TLR (Toll-like receptors)

Beyond the preview

Go deeper on paeoniflorin + cervus and cucumis polypeptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paeoniflorin + cervus and cucumis polypeptide.

Explore the full profile